SOURCE: StockCall


December 31, 2010 09:23 ET

Opinions on Abbott Laboratories and Pfizer Inc. -- Drug Companies Dealing With the Patent Cliff in Their Own Way

JOHANNESBURG, SOUTH AFRICA--(Marketwire - December 31, 2010) - offers investors comprehensive research on the drug manufacturers - major industry and has completed analytical research on Abbott Laboratories (NYSE: ABT) and Pfizer Inc. (NYSE: PFE). Register with us today at to have free access to these researches. 

Major drug manufacturers are experiencing a patent cliff. 2010 saw the expiration of patents on drugs of combined sales worth around 25 billion dollars. In 2011, companies face a further slew of patent expirations of drugs with pooled sales worth about 20 billion dollars. Register now at to have free access to our reports on the drug manufacturers - major industry. is an online platform where investors doing their due-diligence on the drug manufacturers - major industry can have easy and free access to our analyst research and opinions on Abbott Laboratories and Pfizer Inc.; all investors need to do is register for a complimentary membership at

Drug manufacturers are facing this challenging time in a variety of ways. Some like Pfizer Inc. are striking deals with smaller companies which have Abbreviated New Drug Approval to produce and market their products, providing them with a broader portfolio. Some such as Abbott Laboratories are looking to global expansion, opening or acquiring ventures in Asia and Europe. Others are diversifying their interests into less volatile areas such as energy drinks and veterinary health. These decisions to expand and diversify are testament not only to the patent expirations but also an extended period without significant new drugs being successfully discovered. Investors looking for free research on Abbott Laboratories and Pfizer Inc. are welcome to sign up at or

A few are remaining focused on human drug research, hedging their bets on discovering the next big drug but this is viewed as increasingly risky. Those which have decided to remain in the discovery niche are not taking the decision lightly and are focused on internal restructuring and improved productivity. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information